ReviewDrug design, development and therapy2014
Design of oral agents for the management of multiple sclerosis: benefit and risk assessment for dimethyl fumarate.
Review in Drug design, development and therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 27 citations in OpenAlex.
- Glutathione Biology in Neurodegenerative and Metabolic Diseases: Molecular Mechanisms, Pathophysiological Roles, and Therapeutic Perspectives.International journal of molecular sciences · 2026Review
- Differential Protein Expression in Extracellular Vesicles Defines Treatment Responders and Non-Responders in Multiple Sclerosis.International journal of molecular sciences · 2024Article
- Promises of Lipid-Based Nanocarriers for Delivery of Dimethyl Fumarate to Multiple Sclerosis Brain.Methods in molecular biology (Clifton, N.J.) · 2024Article
- Redox Regulation of Nrf2 in Cisplatin-Induced Kidney Injury.Antioxidants (Basel, Switzerland) · 2023Review
- Heme Oxygenase-1 as Therapeutic Target for Diabetic Foot Ulcers.International journal of molecular sciences · 2022Review
- Dimethyl fumarate ameliorates cisplatin-induced renal tubulointerstitial lesions.Journal of toxicologic pathology · 2019Article
- Heme Catabolic Pathway in Inflammation and Immune Disorders.Frontiers in pharmacology · 2019Review
- Quantifying the Benefits of Dimethyl Fumarate Over β Interferon and Glatiramer Acetate Therapies on Work Productivity Outcomes in MS Patients.Neurology and therapy · 2017Article
- Role of Nrf2/HO-1 system in development, oxidative stress response and diseases: an evolutionarily conserved mechanism.Cellular and molecular life sciences : CMLS · 2016Review
- NF-κB Pathways in the Pathogenesis of Multiple Sclerosis and the Therapeutic Implications.Frontiers in molecular neuroscience · 2016Review
- Targeting heme oxygenase-1 and carbon monoxide for therapeutic modulation of inflammation.Translational research : the journal of laboratory and clinical medicine · 2016Review
- ALFF Value in Right Parahippocampal Gyrus Acts as a Potential Marker Monitoring Amyotrophic Lateral Sclerosis Progression: a Neuropsychological, Voxel-Based Morphometry, and Resting-State Functional MRI Study.Journal of molecular neuroscience : MN · 2015Article
- Acute pancreatitis: possible association of dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis.Journal of neurology · 2015Article
- Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview.Therapeutic advances in neurological disorders · 2015Review
- Curbing Inflammation in Multiple Sclerosis and Endometriosis: Should Mast Cells Be Targeted?International journal of inflammation · 2015Review
- Advances in the management of relapsing-remitting multiple sclerosis: role of oral dimethyl fumarate (BG-12).Degenerative neurological and neuromuscular disease · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dimethyl fumarate (DMF) is the most recent oral disease-modifying therapy approved by the US Food and Drug Administration and is indicated for the treatment of relapsing forms of multiple sclerosis (MS). Prior to approval for use in MS, DMF and its active metabolite, monomethyl fumarate, had been used for decades as two of the fumaric acid esters in Fumaderm, a medication used in Europe for the treatment of psoriasis. The unique mechanism of action of DMF remains under evaluation; however, it has been shown to act through multiple pathways leading to shifts away from the Th1 proinflammatory response to the less inflammatory Th2 response. Preliminary data suggest that DMF may induce neuroprotective effects in central nervous system white matter, although further studies are needed to demonstrate these effects on inflammatory demyelination. The DMF Phase III clinical trials demonstrated its efficacy with regard to a reduction in the annualized relapse rate and reductions in new or enlarging T2 lesions and numbers of gadolinium-enhancing lesions on magnetic resonance imaging. DMF has a well-defined safety profile, given the experience with its use in the treatment of psoriasis, and more recently from the DMF clinical trials program and post-marketing era for treatment of MS. The safety profile and oral mode of administration of DMF place it as an attractive first-line therapy option for the treatment of relapsing forms of MS. Long-term observational studies will be needed to determine the effects of DMF on progression of disability in MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.